Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026)

Xilio Therapeutics (XLO) reported Change in Receivables of -$5.0 million for Q1 2026, up 60.0% sequentially from -$12.5 million in Q4 2025.

Xilio Therapeutics (XLO) Change in Receivables (2024 - 2026) Analysis & Trends

Xilio Therapeutics (XLO) has 3 years of Change in Receivables data on file, last reported at -$5.0 million in Q1 2026.

For the quarter ending Q1 2026, Change in Receivables changed N/A year-over-year to -$5.0 million; the trailing twelve-month figure through Mar 2026 stood at $12.5 million (changed N/A YoY), and the FY2025 full-year result was $5.0 million, changed N/A from the prior year.
Change in Receivables improved to -$5.0 million in Q1 2026, from -$12.5 million in the prior quarter.
In the past five years, Change in Receivables ranged from a high of $30.0 million in Q1 2024 to a low of -$12.5 million in Q4 2025.
A 3-year average of $4.2 million and a median of -$5.0 million in 2026 frame the typical range for Change in Receivables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	75.30 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-39.80 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-1.20 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Xilio Therapeutics	148.60 Mn	-1.70 Mn	-	-5.00 Mn

Download Data